Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized trial of ibrutinib versus fixed-duration venetoclax + obinutuzumab versus fixed-duration ibrutinib + venetoclax in previously untreated CLL
MOH_2021-03-24_009558Phase 3Not yet recruiting
- Sponsor
- GCLLSG נציג היזם בישראל: ההסתדרות הרפואית לישראל
- Start
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib monotherapy, Obinutuzumab + venetoclax and Ibrutinib + venetoclax (3 arms). Primary endpoint: Efficacy comparison of continuous ibrutinib versus fixed-duration venetoclax-based combinations. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2021-03-24_009558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-24_009558.